Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
28.01.25
/
50%
€12.20
Target price
28.01.26
€17.25
Performance (%)
-61.48%
End price
29.01.26
€4.70
Summary
This prediction ended on 29.01.26 with a price of €4.70. The BUY prediction by The_Goldman_Sachs_Gr for Myriad Genetics performed very badly with a performance of -61.48%. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Myriad Genetics | -2.622% | -2.622% | 36.330% |
| iShares Core DAX® | 0.073% | 0.242% | 2.887% |
| iShares Nasdaq 100 | -1.344% | -3.371% | 29.208% |
| iShares Nikkei 225® | -2.314% | -7.496% | 56.323% |
| iShares S&P 500 | -0.340% | 0.899% | 23.175% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $29.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat
In the thread Trading Myriad Genetics
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten